Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of IPG11406 Tablets in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT07535489 is registered in ClinicalTrials.gov with Nanjing Immunophage Biotech Co., Ltd as lead sponsor.

NCT NCT07535489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of IPG11406 Tablets in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 7, 2026
Completion date
December 1, 2029
Enrollment
144 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderately to severely active ulcerative colitis (uc)